Company intelligence / Profile preview

HYPHEN BioMed

Neuville-sur-Oise, Ile-de-France, Francehyphen-biomed.com ↗

Ownership: Private
Employees: ~100
Development stage: Commercial

Overview

HYPHEN BioMed offers a comprehensive portfolio of over 500 in-vitro diagnostic and research reagents for the exploration and diagnosis of thrombosis, hemostasis, fibrinolysis, and autoimmunity. Their products are CE marked and some are FDA-cleared; they support both manual and automated laboratory platforms. The company has a strong reputation for innovation in specialized coagulation testing.

Therapeutic areas: Hematology
Modalities: Diagnostic reagent (In-vitro diagnostic)Biologic (for some reagents)Immunological reagent
Industry: Protein Biomarker Diagnostics

Partnerships

Aniara Corporation (North American distribution)

Beyond the preview

Go deeper on HYPHEN BioMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HYPHEN BioMed.

Explore the full profile